Chief Medical Officer, Foody Joanne M. sold 942 shares of Esperion Therapeutics Inc. [ESPR]

0
11

Esperion Therapeutics Inc.’s recent filing unveils that its Chief Medical Officer Foody Joanne M. unloaded Company’s shares for reported $7242.0 on Oct 18. In the deal valued at $7.69 per share,942 shares were sold. As a result of this transaction, Foody Joanne M. now holds 108,135 shares worth roughly $ 0.9 million.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


Then, Warren Eric sold 107 shares, generating $823 in total proceeds. Upon selling the shares at $7.69, the Chief Commercial Officer now owns 53,662 shares.

Before that, Warren Eric sold 255 shares. Esperion Therapeutics Inc. shares valued at $1,765 were divested by the Chief Commercial Officer at a price of $6.92 per share. As a result of the transaction, Warren Eric now holds 53,769 shares, worth roughly $0.45 million.

Credit Suisse downgraded its Esperion Therapeutics Inc. [ESPR] rating to an Underperform from a a Neutral in a research note published on Monday, August 03, 2022; the price target was decreased to $6 from $7. PT values the company’s stock at a premium of -38.5 to its Monday closing price. A number of analysts have revised their coverage, including JP Morgan’s analysts, who increased its forecast for the stock in early May from “an Underweight” to “a Neutral”. H.C. Wainwright began covering ESPR with “Buy” recommendation on March 10, 2022. Credit Suisse revised its rating on October 19, 2021. It rated ESPR as “a Neutral” which previously was an “an Outperform”.

Price Performance Review of ESPR

On Monday, Esperion Therapeutics Inc. [NASDAQ:ESPR] saw its stock fall -2.92% to $8.31. On the same session, the stock had its day’s lowest price of $8.27, but rose to a high of $8.65. Over the last five days, the stock has gained 2.21%. Esperion Therapeutics Inc. shares have risen nearly 66.20% since the year began. Nevertheless, the stocks have fallen -19.63% over the past one year. While a 52-week high of $10.73 was reached on 11/01/22, a 52-week low of $3.28 was recorded on 02/08/22. SMA at 50 days reached $7.57, while 200 days put it at $6.01. A total of 1.53 million shares were traded, compared to the trading of 2.21 million shares in the previous session.

Levels Of Support And Resistance For ESPR Stock

The 24-hour chart illustrates a support level at 8.17, which if violated will result in even more drops to 8.03. On the upside, there is a resistance level at 8.55. A further resistance level may holdings at 8.79. The Relative Strength Index (RSI) on the 14-day chart is 56.69, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.31, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 43.20%. Stochastics %K at 69.25% indicates the stock is a holding.

How much short interest is there in Esperion Therapeutics Inc.?

A steep rise in short interest was recorded in Esperion Therapeutics Inc. stocks on Jul 14, 2022, growing by 1.06 million shares to a total of 12.13 million shares. Yahoo Finance data shows the prior-month short interest on Jun 14, 2022 was 11.07 million shares. There was a rise of 8.74%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 27.30% of the overall stock float, the days-to-cover ratio (short ratio) rose to 15.2.

Esperion Therapeutics Inc. [ESPR] – Who Are The Largest Shareholders?

In filings from Wasatch Advisors, Inc., it is revealed that the company now owns 7,546,008 shares, or roughly 11.34% of the outstanding ESPR shares. In other words, the investor’s shares have fallen by -601,372 from its previous 13-F filing of 8147380.0. Over the last quarter, Bellevue Asset Management AG sold -63,900 shares of Esperion Therapeutics Inc., while The Vanguard Group, Inc. sold -199,439 shares. At present, BlackRock Fund Advisors is holding 3,567,562 shares valued at $23.9 million. Millennium Management LLC owned 2,706,290 shares of the company at the time of its most recent 13F filing, worth $18.13 million.

According to FactSet, Esperion Therapeutics Inc.’s share price will average $11.27 in the next year, based on opinions of analysts polled by the firm. This is up nearly 5.14 percent from its previous closing price of $8.56. Analysts expect Esperion Therapeutics Inc. stock to reach the higher price of $22.00, while the lowest price estimate is $3.00. However, 11 analysts have rated ESPR stock as a Hold in their predictions for 2022.

LEAVE A REPLY

Please enter your comment!
Please enter your name here